Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

被引：0
|
作者：
Chao Jing
Junyun Wang
Mingyue Zhu
Zhigang Bai
Baoyi Zhao
Jun Zhang
Jie Yin
Xiaobao Yang
Zongzhi Liu
Zhongtao Zhang
Wei Deng
机构：
[1] Beijing Friendship Hospital,Department of General Surgery, Medical Oncology Group
[2] Capital Medical University,CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics
[3] Beijing Key Laboratory of Cancer Invasion and Metastasis Research & National Clinical Research Center for Digestive Diseases,Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital
[4] Chinese Academy of Sciences/China National Center for Bioinformation,undefined
[5] Chinese Academic of Medical Sciences and Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Immune checkpoint inhibitors; Molecular targeted therapy; Camrelizumab; Apatinib; Advanced gastric cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2597 / 2608
页数：11
相关论文
共 50 条
  • [41] Neoadjuvant PD-1 inhibitor tislelizumab combined with s-1 plus oxaliplatin in patients with local advanced gastric cancer or gastroesophageal junction adenocarcinoma: Interim results of a single-arm, phase II trial
    Tao, Kaixiong
    Yin, Yuping
    Lin, Yao
    Li, Wei
    Li, Ruidong
    Liu, Weizhen
    Xiong, Zhen
    Zeng, Xiangyu
    Cai, Ming
    Wu, Cuanqing
    Zhang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study
    Cui, Yunlong
    Bao, Xu
    Yu, Ge
    Li, Huikai
    Fang, Feng
    Li, Qiang
    Zhang, Wei
    Wu, Qiang
    Chen, Lu
    Liu, Chen
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: An open-lable, single-arm, phase II study
    Zhou, H.
    Long, B.
    Yu, Z.
    Zhu, J.
    Yang, H.
    Zhang, W.
    Guan, X.
    Zhang, G.
    Li, L.
    Luo, C.
    Cao, H.
    Zhang, S.
    Chen, S.
    He, Q.
    Gan, S.
    Zhou, L.
    Jiang, X.
    Shi, W.
    Huang, Z.
    Mao, J.
    Dong, C.
    Jiao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S66 - S67
  • [44] Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study
    Li, Ning
    Deng, Wenying
    Zhang, Guifang
    Du, Yali
    Guo, Yanwei
    Ma, Yijie
    Wei, Chen
    Bie, Liangyu
    Zhang, Chi
    Song, Tao
    Luo, Suxia
    Fang, Baijun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial
    Pan, Lanlan
    Tian, Yitong
    Wang, Kangxin
    Tang, Jie
    Liu, Jin
    Zhang, Jiaguang
    Wang, Min
    Liu, Jie
    Xu, Hao
    Chen, Xiaofeng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 3300 - 3313
  • [46] Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/ gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial
    Pan, Lanlan
    Tian, Yitong
    Wang, Kangxin
    Tang, Jie
    Liu, Jin
    Zhang, Jiaguang
    Wang, Min
    Liu, Jie
    Xu, Hao
    Chen, Xiaofeng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (06) : 3300 - 3313
  • [47] Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study
    Lu, M.
    Yu, X.
    Chen, Z.
    Zhang, Y.
    Li, Z.
    Zhang, X.
    Yin, F.
    Ye, F.
    Cheng, Y.
    Song, L.
    Xu, J.
    Zhou, J.
    Shi, H.
    Tan, P.
    Fan, S.
    Su, W.
    Shen, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1448 - S1448
  • [48] Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial
    Zhou, Na
    Zhang, Chuantao
    Liu, Dong
    Liu, Kewei
    Wang, Guanqun
    Zhu, Hua
    Zhang, Jianli
    Jiang, Man
    Liu, Ning
    Zhang, Xiaochun
    ONCOLOGIST, 2021, 26 (03): : E374 - E381
  • [49] HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
    Song, Yan
    Li, Ning
    Li, Qun
    Liang, Xinjun
    Zhang, Shu
    Fan, Qingxia
    Yin, Xianli
    Zhuang, Zhixiang
    Liu, Yunpeng
    Zhang, Jingdong
    Kou, Xiaoge
    Zhong, Haijun
    Wang, Xiaofei
    Dou, Yiwei
    Huang, Jing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [50] Clinical efficacy and safety of apatinib combined with docetaxel in second-line treatment for advanced gastric cancer: A prospective study.
    Yang, Mudan
    Gao, Jun
    Xu, Zhou
    Lu, Hongxia
    Yang, Wenhui
    Li, Li
    Li, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345